ATE237324T1 - Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen - Google Patents

Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen

Info

Publication number: ATE237324T1
Authority: AT; Austria
Prior art keywords: pharmaceutical compositions; compositions; neuroprotective pharmaceutical; effective; dexanabinol derivatives
Prior art date: 1994-02-07

Application number

AT95909482T

Other languages

English (en)

Inventor

Raphael Mechoulam

Emil Pop

Mordechai Sokolovsky

Yoel Kloog

Anat Biegon

Original Assignee

Univ Ramot

Yissum Res Dev Co

Pharmos Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-07

Filing date

1995-02-06

Publication date

2003-05-15

1995-02-06 Application filed by Univ Ramot, Yissum Res Dev Co, Pharmos Corp filed Critical Univ Ramot

2003-05-15 Application granted granted Critical

2003-05-15 Publication of ATE237324T1 publication Critical patent/ATE237324T1/de

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical class C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 title 1
230000000324 neuroprotective effect Effects 0.000 title 1
206010029350 Neurotoxicity Diseases 0.000 abstract 2
206010044221 Toxic encephalopathy Diseases 0.000 abstract 2
230000007135 neurotoxicity Effects 0.000 abstract 2
231100000228 neurotoxicity Toxicity 0.000 abstract 2
208000010496 Heart Arrest Diseases 0.000 abstract 1
208000005374 Poisoning Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000009692 acute damage Effects 0.000 abstract 1
230000036770 blood supply Effects 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
230000001010 compromised effect Effects 0.000 abstract 1
HCAWPGARWVBULJ-IAGOWNOFSA-N delta8-THC Chemical class C1C(C)=CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 HCAWPGARWVBULJ-IAGOWNOFSA-N 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
231100000572 poisoning Toxicity 0.000 abstract 1
230000000607 poisoning effect Effects 0.000 abstract 1
230000002829 reductive effect Effects 0.000 abstract 1
230000000707 stereoselective effect Effects 0.000 abstract 1
230000008733 trauma Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Pyrane Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT95909482T 1994-02-07 1995-02-06 Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen ATE237324T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/192,886 US5521215A (en)	1989-11-07	1994-02-07	NMDA-blocking pharmaceuticals
PCT/US1995/001470 WO1995020958A1 (en)	1994-02-07	1995-02-06	Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
ATE237324T1 true ATE237324T1 (de)	2003-05-15

Family

ID=22711431

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95909482T ATE237324T1 (de)	1994-02-07	1995-02-06	Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen

Country Status (10)

Country	Link
US (1)	US5521215A (de)
EP (1)	EP0765160B1 (de)
JP (1)	JPH09511493A (de)
AT (1)	ATE237324T1 (de)
AU (1)	AU690221B2 (de)
CA (1)	CA2183466A1 (de)
DE (1)	DE69530389T2 (de)
IL (1)	IL112572A0 (de)
SG (1)	SG49625A1 (de)
WO (1)	WO1995020958A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5455279A (en) *	1991-04-19	1995-10-03	The Children's Medical Center Corporation	Regimen method of mediating neuronal damage using nitroglycerine
US6299895B1 (en)	1997-03-24	2001-10-09	Neurotech S.A.	Device and method for treating ophthalmic diseases
US5904144A (en) *	1996-03-22	1999-05-18	Cytotherapeutics, Inc.	Method for treating ophthalmic diseases
US6017903A (en)	1996-09-27	2000-01-25	Guilford Pharmaceuticals Inc.	Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) *	1996-09-27	1998-10-20	Guilford Pharmaceuticals Inc.	Treatment of global and focal ischemia using naaladase inhibitors
KR20000036227A (ko)	1996-09-27	2000-06-26	토마스 씨. 서	날라다아제조성물, 글루탐산염 이상 치료법 및 동물내의 뉴우런활성법
DE19706903A1 (de) *	1997-02-21	1998-08-27	Bayer Ag	Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
CA2288693A1 (en) *	1997-05-07	1998-11-12	Unimed Pharmaceuticals, Inc.	Method of improving disturbed behavior and elevating mood in humans
CA2295098A1 (en) *	1997-06-30	1999-01-07	Allergan Sales, Inc.	Calcium blockers to treat proliferative vitreoretinopathy
US20050009884A1 (en) *	1997-06-30	2005-01-13	Dreyer Evan B.	Calcium blockers to treat proliferative retinal diseases
US6110139A (en) *	1997-10-21	2000-08-29	Loubser; Paul Gerhard	Retrograde perfusion monitoring and control system
AU9797598A (en) *	1997-11-14	1999-06-07	Alcon Laboratories, Inc.	Treatment of diabetic retinopathy
GB9807639D0 (en) *	1998-04-14	1998-06-10	Kennedy Rheumatology Inst	Anti-inflammatory agents
JP2002512188A (ja) *	1998-04-21	2002-04-23	ザガバメントオブザユナイテッドステイツオブアメリカ，アズレプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	抗酸化剤及び神経保護剤としてのカンナビノイド類
WO1999057106A1 (en) *	1998-05-04	1999-11-11	The University Of Connecticut	Novel analgesic and immunomodulatory cannabinoids
US7897598B2 (en) *	1998-06-09	2011-03-01	Alexandros Makriyannis	Inhibitors of the anandamide transporter
US7589220B2 (en) *	1998-06-09	2009-09-15	University Of Connecticut	Inhibitors of the anandamide transporter
US7161016B1 (en)	1998-11-24	2007-01-09	University Of Connecticut	Cannabimimetic lipid amides as useful medications
US7276613B1 (en)	1998-11-24	2007-10-02	University Of Connecticut	Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7119108B1 (en) *	1999-10-18	2006-10-10	University Of Connecticut	Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) *	2001-08-31	2008-07-01	University Of Connecticut	Pyrazole analogs acting on cannabinoid receptors
US8084467B2 (en) *	1999-10-18	2011-12-27	University Of Connecticut	Pyrazole derivatives as cannabinoid receptor antagonists
MXPA02005103A (es)	1999-10-18	2003-09-25	Alexipharma Inc	Ligandos selectivos del receptor de canabinoide (cb2) perifericos.
US6943266B1 (en)	1999-10-18	2005-09-13	University Of Connecticut	Bicyclic cannabinoid agonists for the cannabinoid receptor
US6900236B1 (en) *	1999-10-18	2005-05-31	University Of Connecticut	Cannabimimetic indole derivatives
US7741365B2 (en) *	1999-10-18	2010-06-22	University Of Connecticut	Peripheral cannabinoid receptor (CB2) selective ligands
CA2411585A1 (en) *	2000-06-22	2001-12-27	Pharmos Corporation	Novel non-psychotropic cannabinoids
EP1785417A3 (de) *	2000-06-22	2007-08-01	Pharmos Corporation	Neuartige nicht-psychotrope Cannabinoide
US7235584B2 (en) *	2000-06-22	2007-06-26	Pharmos Corporation	Non-psychotropic cannabinoids
US8449908B2 (en) *	2000-12-22	2013-05-28	Alltranz, Llc	Transdermal delivery of cannabidiol
WO2002058636A2 (en) *	2001-01-26	2002-08-01	University Of Connecticut	Novel cannabimimetic ligands
JP2005503998A (ja)	2001-01-29	2005-02-10	ユニバーシティオブコネチカット	受容体選択性のカンナビミメティックアミノアルキルインドール
ATE447403T1 (de) *	2001-04-06	2009-11-15	Univ Illinois	Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen
WO2003005960A2 (en) *	2001-07-13	2003-01-23	University Of Connecticut	Novel bicyclic and tricyclic cannabinoids
CN1589269A (zh) *	2001-10-26	2005-03-02	康涅狄格大学	杂1,2－二氢化茚:一类新型有效的大麻配体
US7029918B2 (en) *	2002-01-25	2006-04-18	Roche Diagnostics Operations, Inc.	Water-soluble derivatives of lipophilic drugs
AU2003265663A1 (en)	2002-08-23	2004-03-11	University Of Connecticut	Keto cannabinoids with therapeutic indications
AU2003256059A1 (en) *	2002-09-05	2004-03-29	Pharmos Corporation	Non-psychotropic cannabinoids for prevention of cognitive impairment
US20050192341A1 (en) *	2002-09-05	2005-09-01	Seth Kindler	Non-psychotropic cannabinoids for prevention of cognitive impairment
EP1567513A2 (de) *	2002-12-04	2005-08-31	Pharmos Corporation	Dexanabinol mit hoher enantiomerenreinheitfür pharmazeutische zusammensetzungen
US8338648B2 (en) *	2004-06-12	2012-12-25	Signum Biosciences, Inc.	Topical compositions and methods for epithelial-related conditions
CN102766128A (zh)	2005-09-29	2012-11-07	阿尔巴尼分子研究公司	δ-9-四氢大麻酚的生成方法
EP2176208B1 (de) *	2007-07-30	2015-01-21	Zynerba Pharmaceuticals, Inc.	Prodgrugs von cannabidiol, zusammensetzungen mit prodgrugs von cannabidiol und verfahren zu ihrer verwendung
US20090247619A1 (en) *	2008-03-06	2009-10-01	University Of Kentucky	Cannabinoid-Containing Compositions and Methods for Their Use
EP3188734A4 (de)	2014-09-02	2018-01-10	The Texas A&M University System	Verfahren zur behandlung einer organophosphatvergiftung
US9585867B2 (en)	2015-08-06	2017-03-07	Charles Everett Ankner	Cannabinod formulation for the sedation of a human or animal
EP3654942A1 (de)	2017-07-20	2020-05-27	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.	Pharmazeutische filmzusammensetzungen zur verabreichung von lipophilen verbindungen in die haut und / oder über die haut
CN111278425B (zh)	2017-09-11	2024-06-11	耶路撒冷希伯来大学伊萨姆研究开发有限公司	用于向脑部经鼻给药药物和用于全身作用的组合物和方法
EP3717014A1 (de)	2017-11-29	2020-10-07	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.	Cannabinoide zusammensetzungen und verfahren
CA3116194A1 (en)	2018-11-04	2020-05-07	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Orally administrable cannabinoids-containing compositions and methods
US12029718B2 (en)	2021-11-09	2024-07-09	Cct Sciences, Llc	Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1464695A (en) *	1974-06-24	1977-02-16	Smithkline Corp	Dibenzo-b,c-pyrans and pharmaceutical compositions thereof
IL48824A (en) *	1976-01-12	1980-05-30	Yissum Res Dev Co	Pharmaceutical compositions containing (3s,js) tetrahydrocanabinol derivatives and some novel compounds of this type
US4209520A (en) *	1977-06-17	1980-06-24	Pfizer Inc.	Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
US4133819A (en) *	1977-06-17	1979-01-09	Pfizer Inc.	Hexahydro-1-hydroxy-9-hydroxymethyl-3-substituted-6H-dibenzo[b,d]pyrans as analgesic agents
IL80411A (en) *	1986-10-24	1991-08-16	Raphael Mechoulam	Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them

1994
- 1994-02-07 US US08/192,886 patent/US5521215A/en not_active Expired - Lifetime
1995
- 1995-02-06 EP EP95909482A patent/EP0765160B1/de not_active Expired - Lifetime
- 1995-02-06 AU AU17433/95A patent/AU690221B2/en not_active Ceased
- 1995-02-06 WO PCT/US1995/001470 patent/WO1995020958A1/en not_active Ceased
- 1995-02-06 JP JP7520787A patent/JPH09511493A/ja active Pending
- 1995-02-06 CA CA002183466A patent/CA2183466A1/en not_active Abandoned
- 1995-02-06 SG SG1996001470A patent/SG49625A1/en unknown
- 1995-02-06 DE DE69530389T patent/DE69530389T2/de not_active Expired - Fee Related
- 1995-02-06 AT AT95909482T patent/ATE237324T1/de not_active IP Right Cessation
- 1995-02-07 IL IL11257295A patent/IL112572A0/xx active IP Right Grant

Also Published As

Publication number	Publication date
EP0765160B1 (de)	2003-04-16
WO1995020958A1 (en)	1995-08-10
DE69530389D1 (de)	2003-05-22
AU690221B2 (en)	1998-04-23
IL112572A0 (en)	1995-05-26
US5521215A (en)	1996-05-28
SG49625A1 (en)	1998-06-15
JPH09511493A (ja)	1997-11-18
EP0765160A1 (de)	1997-04-02
CA2183466A1 (en)	1995-08-10
AU1743395A (en)	1995-08-21
EP0765160A4 (de)	1997-04-09
DE69530389T2 (de)	2004-03-25

Legal Events

Date	Code	Title	Description
2003-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69530389D1 (de)	2003-05-22	Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen
EP1299374A4 (de)	2004-09-22	Neue nicht psychotropische cannabinoide
BG101118A (en)	1998-04-30	Therapeutical compounds
DE69636308D1 (de)	2006-08-10	Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
ATE203019T1 (de)	2001-07-15	Neue (r)-5-carbamoyl-8-fluor-3-n,n- disubstituierte-amino-3,4-dihydro-2h-1- benzopyrane
EE9800080A (et)	1998-10-15	(Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
SE9604786D0 (sv)	1996-12-20	New compounds
BR9909358A (pt)	2000-12-12	Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito
ATE119520T1 (de)	1995-03-15	Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
ATE243196T1 (de)	2003-07-15	Piperidine und pyrrolidine
HUP9602498A2 (hu)	1998-04-28	Antimikrobiális hatású gyógyászati készítmények
CA2243404A1 (fr)	1998-05-28	Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
CA2215470A1 (fr)	1997-08-14	Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
MX9501849A (es)	1997-02-28	Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
AU2030497A (en)	1997-10-01	Propynyl or dienyl biaromatic compounds
MX9403088A (es)	1997-02-28	Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
BR9809234A (pt)	2000-06-27	Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
CA2340734A1 (en)	2000-06-22	Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
ATE151774T1 (de)	1997-05-15	Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
PL355113A1 (en)	2004-04-05	Novel fusidic acid derivatives
AU7076494A (en)	1995-01-17	Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
EP1785417A3 (de)	2007-08-01	Neuartige nicht-psychotrope Cannabinoide
BR9813098A (pt)	2000-08-15	Uso de glicosaminoglicans, preparação farmacêutica, e, combinaçào
ES2184285T3 (es)	2003-04-01	Compuestos farmaceuticos que contienen diclorhidrato de cinconina.
MX9709684A (es)	1998-06-28	Uso de derivados de vitamina d4 para tratamiento de trastornos de la piel.